| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2785207 | Current Opinion in Genetics & Development | 2009 | 6 Pages |
Abstract
Research on PI 3-kinase (PI3K) is undergoing significant shifts in emphasis. Questions that have been dormant for some time are coming to the forefront, such as the relationship of PTEN to PI3K and the role of AKT in PI3K-driven oncogenesis. Two non-alpha isoforms of Class I PI3K are now established as important determinants in cancer: p110β and p110δ. The oncogenic activities of p110β include a non-catalytic function, a finding that will have immediate consequences for drug development.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Developmental Biology
Authors
Peter K Vogt, Marco Gymnopoulos, Jonathan R Hart,